NPPA revises prices of 33 formulation packs including monocomponent human insulin by Eli Lilly

New Delhi, 31 Dec: The National Pharmaceutical Pricing Authority (NPPA) has revised the prices in respect of 33 formulation packs including glipizide with combinations, metronidazole with combinations and monocomponent human insulin. According to the notification dated December 27, the prices for five formulation packs of moncomponent human insulin, manufactured and imported by Eli Lilly and Company, were revised by the price regulator. “NPPA in its 128th Authority Meeting held on 21.12.2012 duly considered the price fixation order and approved the prices of imported formulations having domestic/indigenous substitute as per the guidelines approved in 121st Authority Meeting held on 22.7.2011 for such imported formulations. Accordingly, prices for concerned imported formulations were approved in public interest under various provisions of the DPCO, 1995, in order to ensure fair and reasonable price to consumer public,” the notification said. The price for oxyetetracycline capsule were fixed by the agency at Rs. 10.48 while the rates for 14 formulation packs of glipizide with combinations were revised. Apart from glipizide tablet, they included glipizide+metformin tablet and glipizide+metformin+ pioglitazone tablets. Metronidazole+norfloxacin suspension, prednisolone acetate opthalmic, and ozurdex/retina - dexamethasone intravitreal injection were the other packs for which the agency announced the revised prices. “The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority. These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995,” the notification said. “These prices fixed/notified herein above under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940. The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes herein above within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955,” the agency said.

Pharmabiz